TsETIRIZIN V KLINIChESKOY PRAKTIKE LEChENIYa DETEY S ALLERGIChESKIMI ZABOLEVANIYaMI
- Authors: Revyakina V.A1
-
Affiliations:
- Issue: No 6-2 (2014)
- Pages: 60-63
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286796
- ID: 286796
Cite item
Open Access
Access granted
Abstract
The article presents the modern data on the mechanisms of action and potentials for the use of antihistamines, primarily cetirizine, in the treatment of allergic diseases. The results of application a cetirizine in the therapy of 27 children (10 boys, 17 girls) aged 2-9 years with mild-to-moderate atopic dermatitis with disease duration of 3-5 years are discussed. In addition to cetirizine, patients have received topical glucocorticosteroid (GCS) mometasone furoate. Maximum duration of use of topical GCS therapy was 7 days, and minimal symptoms of the disease in 11 patients were controlled by receiving cetirizine only. At Day 10, the remission of AD was achieved in 23 children; exacerbation of disease was arrested in all patients at the end of the 2nd week. Follow-up for 2-4 months showed that 21 (77.8 %) patients achieved long-term remission of atopic dermatitis, and 6 patients had one episode of mild exacerbation.
Keywords
Full Text
References
- Аллергические заболевания и окружающая среда / Под редакцией В.А. Ревякиной, О.К. Нетребенко. М., 2005. 238 с.
- Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., 1998. 251 с.
- Diepgen T.L. Early Treatment of the Atopic Child Study Group Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol. 2002; 13(4): 278-86.
- Ревякина В.А. Иммунологические основы развития атопического дерматита и новая стратегия терапии. СопзШит Medicum. Педиатрия. 2004; (прил. 1): 31-3
- Stevenson J., Cornah D., Evrard P., et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr. Res. 2002; 52(2): 251 -57.
- Snyder S.H., Snowman A.M. Receptor effects of cetirizine. Ann. Allergy. 1987; 59: 4-8.
- ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr. Allergy Immunol. 1998; 9(3): 116-24.
- Warner J.O. ETAC Study Group. A doubleblinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J. Allergy Clin. Immunol. 2001; 108(6): 929-3 7.
- Цветкова Е.А., Балаболкин И.И. Терапевтическая эффективность Зиртека® у детей с атопическим дерматитом. Тезисы V Российского национального Конгресса «Человек и Лекарство», Москва, 21-25 апреля 1998. C. 253.
- Allegra L., Paupe J., Wieseman H.G., Baelde Y. Cetirizine for seasonal allergic rhinitis in children aged 2-6 years. A double-blind comparison with placebo. Pediatr. Allergy Immunol. 1993; 4(3): 157-61.
- Masi M., Candiani R., van de Venne H. A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Pediatr. Allergy Immunol. 1993; 4(4 Suppl): 47-52.
- Разина Л.А., Балаболкин И.И., Филин B.А. Влияние терапии цетиризином на состояние функции внешнего дыхания у детей, страдающих бронхиальной астмой. Сборник тезисов I Всероссийского конгресса по детской аллергологии «Проблемы раннего выявления, профилактики и терапии аллергических заболеваний у детей». М., 2001. C. 128.
- Cetirizines's fundamental anti-allergic properties are crucial to ETAC's success. ETAC Sci. 1994; 3.
- Simons F.E. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. J. Allergy Clin. Immunol. 1999; 104(2 Pt 1): 433-40.
Supplementary files
